IL17A and metabolic dysfunction-associated steatotic liver disease: In conclusion, this network pharmacology-based study revealed the active compounds and potential mechanism through which FLD is effective on NAFLD by modulating various pathways, such as pathways in cancer, Th17 cell differentiation, and IL-17 signaling pathway.